Table 6.
Ultrasound changes of NAFLD grade and liver enzymes at baseline and end of trial in patients.
| Control (n = 45) | Intervention (n = 42) | b p | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | End-of-trial | a p | Baseline | End-of-trial | a p | Baseline | End-of-trial | ||
| Liver enzymes | ALT | 36.466 ± 9.734 | 36.600 ± 10.688 | 0.672 | 36.452 ± 10.231 | 31.571 ± 11.495 | <0.001 | 0.855 | 0.005 |
| AST | 24.422 ± 8.661 | 23.955 ± 8.702 | 0.194 | 25.381 ± 9.057 | 17.119 ± 9.239 | <0.001 | 0.627 | <0.001 | |
|
| |||||||||
| Fatty liver (%) | No fatty liver | 0 | 0 | c0.999 | 0 | 8 (19) | c0.002 | d0.974 | d0.009 |
| Grade I | 32 (71.1) | 31 (68) | 30 (41.4) | 24 (57) | |||||
| Grade II | 13 (28.9) | 14 (31) | 12 (28.6) | 10 (23) | |||||
Data are means ± SDs. ALT: alanine aminotransferase; AST: aspartate aminotransferase. aObtained from Wilcoxon test. bObtained from Mann-Whitney U test. cObtained from sign test. dObtained from Chi-square test.